The Ups and Downs of the START Trial with Stimuvax Immunotherapy


One of the highest profile clinical studies over the last few years has been the START trial of Stimuvax, also known as L-BLP-25 or tecemotide, an immunotherapy that looked promising in a randomized phase II trial that led to a subsequent phase III trial that administered Stimuvax or placebo after chemo and radiation for locally advanced (stage III) NSCLC, as described more in this post about STIMUVAX and the START trial from early 2007.

High Profile Failure for Stimuvax: What Does it Mean for the Future of Immunotherapy in Lung Cancer?


Here's a video I just did on the disappointing results of the START trial with Stimuvax, an immunotherapy that was very promising but didn't actually pan out, but why might that have happened, and what does it mean for the future, with other clinical trials with prominent immune-based treatments that have also looked promising in lung cancer?


What do you think? Are you optimistic about Lucanix and the MAGE-A3 trial?

Subscribe to START trial